21
(Paracelsus: 1493-1541) 22 Toxicology is the study of the nature, effects and 23 detection of poisons and the treatment of poisoning. 24 Poisons can be substances that are inherently toxic to 25 tissues, adversely affect physiological function or thera- 26 peutic substances taken in excess. Injury can result not 27 only from the direct effects of the poison but indirectly 28 from injuries sustained while the patient is intoxicated or 29 in various phases of withdrawal. This is particularly 30 relevant to those affected by sensorium altering substances 31 such as opioids, cocaine, amphetamines, ketamine or with 32 compounds emerging from clandestine labs purporting to 33 produce 'legal highs' or 'herbal highs'. Anaesthetists use 34
actual (e.g. muscle relaxants) or potential poisons daily but 35 are either capable of managing their effects (e.g. venti-36 lation) or carefully titrate their administration to avoid 37 toxicity and will be already familiar with the pharma- 38 cology of many of these substances. The drugs may also 39 interact with those used peri-operatively and therefore it 40 is apposite to understand the toxicology of these 41 substances, when practising in anaesthesia or intensive 42 care. This review will focus on illicit substances. These 43 have been a problem, of course, for many years but the 44 range of drugs is increasing along with accessibility as 45 many of these substances can be manufactured in illegal 46 laboratories and even sold via the internet. We will first 47 place the problems in context, provide some succinct 48 information on some of the compounds, with anaesthetic 49 implications where available, and conclude with recent 50 developments in managing patients following ingestion. 51 Since i has not been possible to study many of these t u 52
compo nds in clinical trials or even in humans as they 53 may have no therapeutic indication, the evidence base for anaesthetic implications is rather thin, based on case reports and ⁄ or anecdotal experience. Although numerically important, opioid and benzodiazepine overdose will not be covered here as the pharmacological and toxicological aspects should be sufficiently familiar to most anaesthetists.
Epidemiology of poisoning
Poisoning can affect all age groups. Figures from the Centre for Disease Control and Prevention estimated that in 2009, 41,592 poisoning deaths occurred in the United States, three quarters of which were deemed unintentional. This was second only to motor vehicle accidents as a cause of unintentional injury and death for all ages. It was estimated that in the preceding year over 91 per cent of such deaths were caused by drugs, most commonly analgesics, which includes methadone, hydrocodone and oxycodone, followed by cocaine and heroin [1] . Across England and Wales, figures from the Office for National Statistics showed that of the 2747 drug poisoning deaths in 2010, 1784 were attributable to drug misuse and, again, most commonly associated with heroin and morphine. Opioids still dominate among the substances of abuse to be implicated as a cause of death, but cocaine, amphetamines and the newer psychoactive substances together come close to one tenth of deaths [2] . Those that manage to make it into the statistics may represent the tip of the iceberg. Based on data from the British Crime Survey of 2009 ⁄ 2010, it is estimated that in the 16-59 age group, 6.6% had used cannabis, 2.4% powdered cocaine and 1.6% ecstasy in the year of the survey [3] . Drug intoxicated individuals may be accident prone, from both compromised judgement and motor skills. The latter is supported by data from Norway where 1 close to three quarters of drivers with blood positive only 2 for amphetamines and methamphetamines were perfor-3 mance-impaired in clinical testing [4] . 4 5 Historical perspective of substances of abuse 6 7 A more detailed review on this interesting area can be 8 found in an editorial by King and Kicman [5] and a brief 9
summary is provided here. Since 2005, the term 'new 10 psychoactive substances' has been adopted by the Euro-11
pean Community to describe what was once referred to as 12 'designer drugs' or 'legal highs'. Traditional drugs of abuse 13 such as opioids, cocaine, amphetamines and cannabinoids 14
had their roots in traditional medicine, where they had 15 and still have therapeutic roles, but their use is tightly 16 regulated. Designer drugs are essentially chemical ana-17 logues of some of these controlled substances, 'designed' 18
as it were, to provide a similar experience to the parent 19 compound. Initially fuelled by the demand to replicate 20 the highs produced by opioids, this trend fell out of 21 favour following the discovery of the now well-known 22 neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahy-23 dropyridine) produced in the synthesis of MPPP 24
(1-methyl-4-phenyl-4-propionoxypiperidine), a reverse es-25
ter of pethidine. This contaminant destroys dopaminergic 26 neurons, thus chemically inducing Parkinson's disease. 27 The next era of designer drugs involved the manipu-28 lation of amphetamine, producing an array of substances 29 that energise the consumer and elicit feelings of euphoria 30 and empathy. The terms 'empathogens' or 'entactogens' 31 were used to describe these phenethylamine compounds 32 to which ecstasy belongs. Although not a designer drug as 33 such, gamma-hyroxybutyrate was also popular in the club 34 scene but once its status changed to being a schedule 35 drug, it too underwent modification and gamma butyro-36 lactone became prevalent. Tryptamine derivatives were 37 also available in the 1990s alongside the phenethylamines. 38 In the early 2000s, piperazine compounds arrived after 39 being considered unsuitable for therapeutic use by 40 pharmaceutical companies. Further trawling of the lines 41 of failed pharmaceutical products for potential 'legal 42
highs' yielded the cathinone derivatives including 43 mephedrone. As these products were derived from 44 chemicals obtainable from legal sources, their promulga-45 tion and distribution became more extensive. 46 47 Toxidrome 48 49
Most of the newer substances of abuse have actions at 50 multiple receptor types but may differ in their patterns of 51 effects [6] . Drugs that produce a sympathomimetic 52 syndrome do so by inhibiting reuptake of catecholamines, 53 eliciting mainly stimulatory effects in the user and examples of such agents include benzylpiperazine, mephedrone and diphenylprolinol. Other drugs act predominately on the serotonergic system and thus manifest signs of serotonin syndrome in toxicity. Those agents that tend to produce entactogenic feelings (e.g. phenylpiperazines, methylone) do so by causing serotonin release in the CNS whereas those with hallucinogenic properties (e.g. 5-methoxy-N,N-diisopropyltryptamine, 2,5-dimethoxy-4-bromoamfetamine) are serotonin receptor agonists [6] .
Cannabinoids
Cannabis is probably one of the most frequently used recreational drugs and is consumed as a mixture of dried shredded flowers and leaves of the hemp plant Cannabis sativa (marijuana), as resinous secretions of the cannabis plant (hashish) or synthetically as a yellow resinous oil (dronabinol). Delta-9-tetrahydrocannabinol (THC) is believed to be the most psychoactive component of cannabinoids contained in cannabis. Although its toxicological effects may be familiar to some, it is worth bearing in mind that advances in cultivation methods have enabled higher THC yield from plants and that hashish oil or resin can contain a very high quantity of THC. This potentially would increase the likelihood of more significant levels in the blood and enhanced intoxication. Although risk perception following cannabis use is less impaired than with alcohol, it is one of the most common drugs detected in drivers involved in motor vehicle accidents [7] .
Given the prevalence of its use, it has been suggested that a history of illicit drug and especially cannabis use should be obtained routinely in the pre-anaesthetic assessment, although patients may be reticent to disclose it [8] . It is also difficult to predict the degree of intoxication as this is not linearly related to plasma levels [9] . The nature of the interaction between the sedative effects of cannabis and general anaesthesia may not be easily predictable. There is a lack of data in humans but animal studies indicate that THC may prolong the sedative effect of general anaesthesia [10, 11] . Acute intoxication with agitation can be treated with benzodiazepines or, probably more safely, with alpha-2 agonists [12] . Smoking marijuana leads to a greater respiratory burden of carbon monoxide and tar than smoking a similar quantity of tobacco [13] ; it is also claimed that it causes more airway irritation due to the higher temperature at which marijuana leaves burn [14] . Therefore, one should be prepared for dealing with airway complications such as bronchospasm. Recent inhalation of marijuana smoke before anaesthesia has been associated with uvular oedema [15] . Tachycardia is 1
probably the most common cardiovascular problem but 2 postural hypotension may occur at higher doses. [19, 20] . Anaesthesia for non-intoxicated patients with urine positive for cocaine metabolites appears to be safe if the QTc interval is less than 500 ms [21] .
Regional anaesthesia may be difficult to perform in the cocaine abusing patient. Combative behaviour and altered sensorium may preclude one from obtaining informed consent or getting cooperation to perform certain blocks or procedures. Cocaine use can induce thrombocytopaenia [22] but a formal platelet count is probably unnecessary for an otherwise healthy cocaine user. Hypertension or hypotension may occur with the latter requiring direct vasopressors such as phenylephrine for control. There may be altered pain perception from changes in opioid receptor density [23] .
Amphetamines
The term amphetamine is short for alpha-methylphenethylamine and these are essentially a group of indirectly acting sympathomimetic compounds with powerful CNS stimulating effects. Various compounds of abuse have been synthesised from this molecule with various substitutions. One of the better known drugs in this class is 'Ecstasy', the name of which can be a rather undifferentiated term used to describe several compounds related to MDMA (3,4 -methylenedioxymethamphetamine). Chemically they resemble adrenaline and dopamine which is reflected in their biological effects. Furthermore, the methylenedioxy (-O-CH2-O-) substitution on the aromatic ring confers properties akin to the hallucinogen mescaline [24] . Thus, the popularity of Ecstasy is its ability to elevate the user's energy levels in addition to enhancing mood with feelings of euphoria and empathy.
Methylenedioxymethamphetamine causes an acute increase in serotonin, noradrenaline and dopamine in synaptic junctions from both increased secretion and reduced reuptake. This leads to a depletion of stores that accompany the withdrawal of the drug. As these neurotransmitters are involved with the control of mood, thermoregulation, sleep and appetite, it explains the pleasurable and undesirable effects of Ecstasy. Typically it has an onset of an hour after oral ingestion with effects lasting 4-6 h, and a plasma half-life of around 7 h. Blood levels often do not correlate well with the severity of systemic effects. After withdrawal from Ecstasy, users may feel very tired and low and need a long period of sleep to recover. Major side effects include hyperpyrexia from over exertion or from central activation of heat generation and conservation mechanisms with consequent rhadomyolysis. There is some anecdotal evidence for the 1 use of Dantrolene to assist cooling [25] . Serotonin 2 syndrome, hyponatraemia, isolated liver failure, cerebro-3 vascular accident or sudden death may also be seen. 4 Hyponatraemia results from excessive drinking of hypo-5 tonic fluids by users to prevent hyperthermia as well as 6
increased antidiuretic hormone secretion [26] . Liver 7 failure can occur as part of the multi-organ failure 8 accompanying rhabdomyolysis or may be the result of an 9
idiosyncratic immune-mediated reaction [27] . available, rapid urine screen for cocaine metabolites may 37 aid in the differential diagnosis. 38 39 40 New psychoactive substances 41 42 Legal highs refer to substances with psychoactive prop- [30] . They can be synthesised with relative ease from compounds, the majority of which can be obtained legally in reasonable quantities from commercial suppliers. As quality control is not a priority of recreational drug laboratories, toxic levels of these substances may be reached accidentally in consumers.
Cathinone compounds
One class of compounds to emerge among the designer drug scene early this millennium is the cathinone derivatives. Cathinone is a psychostimulant derived from fresh leaves of the khat shrub, a plant that is naturally found in Africa and the Arabian peninsula, where the practice of chewing these leaves to obtain a high has been around for many centuries. Just before the isolation of the active ingredient from the plant in 1930, two related synthetic compounds, ephedrone (methcathinone) and mephedrone (4 methylmethcathinone) were produced, the former being marketed as an antidepressant in the USSR [31] . Cathinone was only later isolated from khat in 1975, and the abuse potential of cathinone-derived products was soon recognised, leading to a number (but not all of) its related compounds being restricted. Mephedrone had been popular among abusers and it is snorted or, more commonly, swallowed either neat or dissolved in a beverage to avoid nose burns. The duration of effect is 2-4 h after oral ingestion. From in vitro synaptosomal studies, cathinone-related compounds appear to augment the release of dopamine and noradrenaline [32] . They appear to have a more potent inhibitory effect on monoamine oxidase when compared with amphetamines but a less pronounced effect on serotonin release and reuptake.
Upon consumption, they produce psychostimulatory as well as hallucinogenic effects, with an accompanying peripheral cardiovascular effect attributable to sympathetic activation. In this way, their effects are somewhat similar to those seen with amphetamine use. The toxic consequences are therefore extensions of these pharmacodynamic properties and deaths have been attributable to their use.
Piperazine compounds
Similar to other 'designer' drugs, piperazine compounds began life as failed therapeutics. Originally developed as an antihelminth, it was later investigated as an antidepressant when its potential abuse was recognised because it has similar effects to amphetamines. Benzylpiperazine has a predominately dopaminergic effect causing the release of this neurotransmitter as well as serotonin from 2012 The Authors  1 neurons [33] . In vitro studies also suggest that it causes 2 noradrenaline release from peripheral sympathetic nerve 3
fibres . The other popular piperazine compound trifluo-4 romethylphenylpiperazine acts more on the serotoniner-5
gic system by binding its receptors and inhibiting its 6 reuptake. When taken together, it emulates the effect of 7
Ecstasy. Like other designer drugs, the relationship 8 between toxicity and dose is not always predictable [33] . 9 10 Tryptamines 11 12
Understandably there are many gaps in the pharmaco-13
logical and toxicological profiles of these compounds in 14 humans, as the identity, purity, doses and time of 15 ingestion by affected patients are not known. Therefore, 16 the interaction these may have with anaesthesia is even 17 more of an unknown quantity. However, a number of 18 these agents mimic the actions of endogenous neuro-19
transmitters as well as inhibiting their reuptake. It stands 20
to reason that precautions similar to those exercised for 21 patients on monoamine oxidase inhibitors, selective 22 serotonin reuptake inhibitors or selective noradrenaline 23 reuptake inhibitors, should be taken for patients suspected 24 to have consumed these drugs. Their sympathomimetic 25 effects render gauging depth of anaesthesia by purely 26 3 haemodynamic means a difficult undertaking. Although 27 depth of anaesthesia monitoring may theoretically miti-28 gate some of this difficulty, the intrinsic effect of these 29 stimulants on the processed EEG is not known. Having 30 reuptake inhibitor ability, it is not known whether these 31 agents accentuate endogenous catecholamine responses. 32 33 34 Recent developments in the general 35 management of poisoning 36 Much of the acute management of poisoning occurs in 37 the emergency department or intensive care unit and has 38 been extensively covered in toxicology texts. In general, a elimination. Substances amenable to removal by dialysis are generally those which are water soluble and small. However, most psychoactive substances are, by nature, lipid soluble to facilitate passage across the blood brain barrier. Since the introduction of intravenous lipid emulsion (ILE) as a rescue therapy for local anaesthetic overdose, there have been a number of reports of ILE improving level of consciousness after overdoses of psychotropic drugs thus averting the need for intubation and ventilation [34] [35] [36] . Of particular interest is a report of improvement in cardiovascular stability following ILE administration in a patient with cocaine overdose [37] . One of the proposed mechanisms of efficacy involves an expanded plasma lipid phase in reducing free drug levels.
In vitro modelling studies predict that the more lipid soluble and the larger a drugs volume of distribution, the greater will be the decrease in serum concentration after lipid administration [38] . However, under certain animal experimental conditions, ILE can actually deepen the depth of thiopental-induced anaesthesia, thus challenging this simplistic view of ILE acting merely as a lipid sink [39] . A systematic review of the literature up to June 2009 drew similar conclusions of possibly some benefits of ILE in lipophilic drug overdoses based on mainly case reports and animal studies [40, 41] . There have not been reports of major adverse reactions among those studies reviewed. However, many undesirable effects of ILE are known when it is used as part of total parental nutrition but it is not likely that hypersensitivity would present following acute administration of ILE [42] . Another important aspect of managing psychostimulant toxicity is the symptomatic control of cardiovascular and CNS overstimulation. The use of the alpha 2 adrenoceptor agonist dexmedetomidine for alleviating withdrawal symptoms from sedative use has been widely reported. Its inhibitory effects on central sympathetic outflow have recently been exploited as a means of attenuating the acute sympathomimetic effects of cocaine use. Dexmedetomi-) dine at 0.1 and 0.3 lg.kg 1 potentially necessitating more invasive techniques for 53 increase in sympathetic nerve activation and skin vascular resistance in human volunteers receiving 2 mg.kg )1 of intranasal cocaine [43] . Clinically, it has been reported to be used successfully in alleviating cocaine-induced hypertensive crisis in a patient with aortic dissection [44] . From the CNS point of view, dexmedetomidine has been shown experimentally to counter the decrease in seizure threshold from cocaine toxicity [45] . There is another report of dexmedetomidine use in the treatment of agitation accompanying overdoses of dextromethorphan and MDMA [46] . Thus, this drug has important advantages in the management of several aspects of stimulant overdose and acute withdrawal syndromes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40 4  41  42 5  43  44  45  46  47  48  49  50  51  52  53   Conclusions The true extent of poisoning with psychoactive substances remains undefined but is likely to be underestimated. A lack of quality control and changes in production techniques can yield illicit drugs with a high concentration of the active substance that, in turn, increases the potential for eliciting a greater severity of toxicity. This problem is widespread in society and indications are that new designer drugs are becoming increasingly available [6] . It is almost inevitable that many anaesthetists will be engaged in the care of those poisoned by these substances. The acute cardiac and cerebral toxicity associated with cocaine, amphetamines and cathinone derivatives are mainly attributable to elevated concentrations of catecholamines in nerve endings subsequent to enhanced release and reduced reuptake to various degrees. Haemodynamic instability and changes in anaesthetic and analgesia requirements are probably in those requiring surgery. While the toxicological profile of individual classes of poisons may appear discrete, it is also very important to be cognizant of the likelihood of coingestion of different substances, with the clinical picture being overwhelmed with one major substance, quite often alcohol. The use of intravenous lipid emulsion is showing promise in the treatment of drug overdoses. Dexmedetomidine has a promising role as it dampens sympathetic hyperactivity, is analgesic, produces sedation and relieves agitation without respiratory depression. However, further clinical experience with these agents is required to more clearly delineate indications for their use .  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17   6   18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 
